Insider trading

Period: 120 months Stock: NKTR Share of holding: 50% or more × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

15 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

15 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

15 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

15 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
15 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
15 decisions over 120 months Remove this filter
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

15 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
13 Sep 2022
EASTHAM KARIN Director
Sold, plan not stated
$76.77K 21,267 at 3.61
62.0%
Sold half or more
6 Apr 2018
Doberstein Stephen K SVP & Chief Scientific Officer
Sold, plan not stated
$10.13M 110,500 at 91.69
62.1%
Sold half or more
5 Apr 2018
Lingnau Lutz Director
Sold, plan not stated
$3.05M 30,000 at 101.74
52.2%
Sold half or more
8 Nov 2017
Doberstein Stephen K SVP & Chief Scientific Officer
Sold, plan not stated
$9.03M 300,000 at 30.09
90.6%
Sold half or more
7 Nov 2017
Doberstein Stephen K SVP & Chief Scientific Officer
Sold, plan not stated
$1.94M 75,409 at 25.78
70.8%
Sold half or more
5 Oct 2017
Doberstein Stephen K SVP & Chief Scientific Officer
Sold, plan not stated
$1.09M 43,677 at 24.97
58.4%
Sold half or more
2 Oct 2017
Labrucherie Gil M SVP & Chief Financial Officer
Sold, plan not stated
$2.93M 120,000 at 24.45
65.4%
Sold half or more
2 Oct 2017
Gergel Ivan P. SVP & Chief Medical Officer
Sold, plan not stated
$1.37M 56,704 at 24.21
57.7%
Sold half or more
29 Sep 2017
Gergel Ivan P. SVP & Chief Medical Officer
Sold, plan not stated
$1.04M 43,296 at 24.04
51.0%
Sold half or more
18 Jul 2017
Gergel Ivan P. SVP & Chief Medical Officer
Sold, plan not stated
$1.16M 54,920 at 21.10
55.8%
Sold half or more
14 Jul 2017
Lingnau Lutz Director
Sold, plan not stated
$622.80K 30,000 at 20.76
56.1%
Sold half or more
5 Apr 2017
Hora Maninder SVP Pharma Dev & Mfg Ops
Sold, plan not stated
$3.91M 180,000 at 21.70
73.9%
Sold half or more
5 Apr 2017
Doberstein Stephen K SVP & Chief Scientific Officer
Sold, plan not stated
$2.17M 100,000 at 21.70
74.3%
Sold half or more
20 Mar 2017
Thomsen Jillian B. SVP & Chief Accounting Officer
Sold, plan not stated
$2.22M 112,500 at 19.69
66.9%
Sold half or more
2 Mar 2017
Labrucherie Gil M SVP & Chief Financial Officer
Sold, plan not stated
$2.54M 167,506 at 15.15
70.7%
Sold half or more
Showing 1–15 of 15.